Nektar Therapeutics (NKTR)
51.12
-6.62
(-11.47%)
USD |
NASDAQ |
Dec 11, 16:00
52.00
+0.88
(+1.72%)
After-Hours: 06:09
Nektar Therapeutics Research and Development Expense (TTM): 116.36M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly & Co. | 12.56B |
| Amicus Therapeutics, Inc. | 142.29M |
| Regeneron Pharmaceuticals, Inc. | 5.097B |
| Rigel Pharmaceuticals, Inc. | 28.24M |
| Zevra Therapeutics, Inc. | 16.83M |